|
| 38092228 | Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. | Ann Oncol | 2024 |
| 37906649 | Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients. | Clin Cancer Res | 2024 |
| 38070147 | Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance. | Neuro Oncol | 2024 |
| 37903319 | Reply to Y. Yoshitomi et al. | J Clin Oncol | 2024 |
| 37952893 | Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer? | Ann Oncol | 2024 |
| 37548439 | Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents. | Oncologist | 2024 |
| 38049623 | Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping. | Nat Med | 2024 |
| 36379186 | Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. | Eur J Cancer | 2023 |
| 37865722 | Liquid biopsy epigenomic profiling for cancer subtyping. | Nat Med | 2023 |
| 37562695 | Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2. | Crit Rev Oncol Hematol | 2023 |
| 37633306 | Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. | Lancet | 2023 |
| 37800595 | Managing adverse events of sacituzumab govitecan. | Expert Opin Biol Ther | 2023 |
| 37703594 | Artificial intelligence as an adjunct tool for breast oncologists - are we there yet? | ESMO Open | 2023 |
| 38061009 | Endometrial Cancer Risk Among Germline <i>BRCA1</i>/<i>2</i> Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps. | JCO Precis Oncol | 2023 |
| 37615687 | Correction: PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. | J Exp Med | 2023 |
| 37948596 | The latest breakthrough in breast cancer treatment. | Clin Adv Hematol Oncol | 2023 |
| 37994878 | Interstitial lung disease and CDK4/6 inhibitors in the treatment of breast cancer. | Expert Opin Drug Saf | 2023 |
| 37788154 | Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER study. | Future Oncol | 2023 |
| 37741273 | Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8. | Breast | 2023 |
| 37693537 | Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy. | bioRxiv | 2023 |
| 37938529 | Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan. | Curr Oncol Rep | 2023 |
| 37980405 | Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer. | Nat Commun | 2023 |
| 37499870 | Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment. | Ann Oncol | 2023 |
| 37568813 | Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities. | Cancers (Basel) | 2023 |
| 37637072 | Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer. | Front Oncol | 2023 |
| 37192427 | Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement. | JCO Oncol Pract | 2023 |
| 36951169 | Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts. | Cancer | 2023 |
| 36949066 | The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer. | NPJ Breast Cancer | 2023 |
| 37348019 | AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. | J Clin Oncol | 2023 |
| 37450351 | Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer. | Cancer Res | 2023 |
| 37046675 | Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer. | Cancers (Basel) | 2023 |
| 37210568 | Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies. | Oncologist | 2023 |
| 37146620 | Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply. | Lancet Oncol | 2023 |
| 37207309 | Detecting and Managing T-DXd-Related Interstitial Lung Disease: The Five "S" Rules. | JCO Oncol Pract | 2023 |
| 37103927 | Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. | JAMA Oncol | 2023 |
| 37103916 | Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. | JAMA Oncol | 2023 |
| 37269905 | ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. | Ann Oncol | 2023 |
| 37268724 | Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. | Nat Med | 2023 |
| 37268625 | Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer. | NPJ Breast Cancer | 2023 |
| 37433103 | Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. | J Clin Oncol | 2023 |
| 37296177 | Optimizing the safety of antibody-drug conjugates for patients with solid tumours. | Nat Rev Clin Oncol | 2023 |
| 36997605 | Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan. | NPJ Breast Cancer | 2023 |
| 37356327 | Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool. | Eur J Cancer | 2023 |
| 37194964 | Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial. | J Am Coll Surg | 2023 |
| 36858723 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. | Lancet Oncol | 2023 |
| 36813113 | Elacestrant: who are optimal candidates for the first oral SERD? | Ann Oncol | 2023 |
| 36691884 | The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. | Expert Rev Anticancer Ther | 2023 |
| 36583555 | Survival in male breast cancer over the past 3 decades. | J Natl Cancer Inst | 2023 |
| 36688919 | PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. | J Exp Med | 2023 |
| 36435606 | Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer. | Hematol Oncol Clin North Am | 2023 |